Eli Lilly / Lilly / PMOD Technologies Ltd. / Millipore / Nuclear Medicine Inc. / CBC / GE Healthcare / Suzuki / 3Lilly Research Laboratories / /
Country
Sweden / /
Currency
VND / / /
EntertainmentAwardEvent
Jussi / /
Event
Product Issues / FDA Phase / Business Partnership / /
Facility
National Institute of Mental Health / Center Dr. / Lilly Corporate Center / Pike VW / /
IndustryTerm
in vivo imaging development / vivo imaging / imaging / quantitative post-processing / brain imaging / in vivo imaging / image analysis / /
MedicalCondition
MS / dissociation / human brain tumors / several neuropsychiatric disorders / N18TG2 neuroblastoma cells / medical and psychiatric illness / brain cells / inflammation / /
Organization
Department of Clinical Neuroscience / NIH PET Department / Finnish Medical Foundation / Paulo Foundation / Academy of Finland / Society of Nuclear Medicine / Finnish Foundation for Alcohol Studies / Yrj¨o Jahnsson Foundation / U.S. Food and Drug Administration / Finnish Cultural Foundation / Research Foundation of Orion Corporation / Jalmari and Rauha Ahokas Foundation / Instrumentarium Foundation / International Criminal Court / National Institute of Mental Health / /
Person
Robert B. Innis / Maria D. Ferraris Araneta / Van Laere / Kimberly Jenko / Barbara Scepura / William C. Kreisl / Pavitra Kannan / Kacey Anderson / / /
Position
model for additional analyses / representative / /
Product
18F-FMPEP / Tao / measurements / CB1 / /
ProvinceOrState
Vermont / Maryland / South Dakota / /
Technology
Neuroscience / tomography / drug screening / JAVA / /
Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands Garth E. Terry1,2, Jussi Hirvonen1, Jeih-San Liow1, Sami S. Zoghbi1, Robert Gladding1, Johan